Presentation on Tuesday, October 12th at 3:00
PM EST
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha
Cognition”, or the “Company”), a biopharmaceutical company
committed to developing novel therapies with the potential to
transform the lives of people with debilitating neurodegenerative
disorders, is pleased to announce that it will be presenting at the
14th annual Main Event on Tuesday, October 12th at 3:00 PM EST at
the Luxe Sunset Bel-Air in Los Angeles. Michael McFadden, CEO of
Alpha Cognition, will provide an overview of the Company's
business, highlighting the Company’s lead asset, ALPHA-1062, as
well as its early stage asset, ALPHA-0602, during the presentation.
The company will also host investor meetings after the presentation
on Tuesday.
Event: LD Micro Main Event Date: Tuesday, October
12th Time: 3:00 PM EST
Register to watch the virtual presentation here.
Summary of LD Micro Main Event (XIV)
The 2021 LD Micro Main Event will be held at the Luxe Sunset
Bel-Air in Los Angeles from Tuesday, October 12th to Thursday,
October 14th.
The festivities run from 8 AM PT - 5:30 PM PT on the 12th and
13th with a morning session on the 14th.
This three-day, investor conference is expected to feature
around 150 companies, presenting for 25 minutes each, as well as
several influential keynotes in person.
For more info, please contact Dean@ldmicro.com
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical
company dedicated to developing treatments for under-served
neurodegenerative diseases, such as Alzheimer's Dementia and
Amyotrophic Lateral Sclerosis (ALS).
ALPHA-1062, is a patented new chemical entity that has
demonstrated safety and improved tolerability in human clinical
trials. It is being developed as a new generation
acetylcholinesterase inhibitor for the treatment of Alzheimer's
disease, with minimal gastrointestinal side effects and novel
routes of administration. ALPHA-1062's active metabolites are
differentiated from donepezil and rivastigmine in that they may
sensitize neuronal nicotinic receptors, most notably the alpha-7
subtype, which is known to have a positive effect on cognition.
ALPHA-1062 is also being developed in combination with memantine to
treat moderate to severe Alzheimer's dementia and in a nasal spray
formulation to treat traumatic brain injury.
ALPHA-0602 (Progranulin) is expressed in several cell types in
the central nervous system and in peripheral tissues, regulates
cell survival and certain inflammatory processes, and plays a major
role in regulating lysosomal function and microglial responses to
disease. Its use for the treatment of neurodegenerative diseases
has been patented by the Company and granted an Orphan Drug
Designation.
About LD Micro (NASDAQ: SRAX)
LD Micro aims to be the most crucial resource in the micro-cap
world. Whether it is the index, comprehensive data, or hosting the
most significant events on an annual basis, LD's sole mission is to
serve as an invaluable asset for all those interested in finding
the next generation of great companies.
http://www.ldmicro.com
Neither TSX Venture Exchange (the “TSX-V”), OTC Markets Group,
nor the TSX-V’s Regulation Services Provider (as that term is
defined in policies of the TSX-V) accepts responsibility for the
adequacy or accuracy of this release.
Forward-looking Statements
This news release is not, and under no circumstances is to be
construed as, an advertisement or a public offering of securities.
No securities commission or similar authority in Canada or in any
other jurisdiction has reviewed or in any way passed upon this news
release or the merits of the securities described herein and any
representation to the contrary is an offence.
This news release includes forward-looking statements within the
meaning of applicable securities laws. Except for statements of
historical fact, any information contained in this news release may
be a forward‐looking statement that reflects the Company’s current
views about future events and are subject to known and unknown
risks, uncertainties, assumptions and other factors that may cause
the actual results, levels of activity, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Forward‐looking
statements can be identified by the words “may,” “might,” “will,”
“could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “target,” “seek,” “contemplate,” “continue”
and “ongoing,” or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward‐looking statements in this news release include statements
regarding the Company’s business strategy, market size, potential
growth opportunities, capital requirements, clinical development
activities, the timing and results of clinical trials, regulatory
submissions, potential regulatory approval and commercialization of
the technology. Although the Company believes that we have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. The Company cannot assure that
the actual results will be consistent with these forward-looking
statements as a result of known and unknown risks, uncertainties,
assumptions and other factors. These risks, uncertainties,
assumptions and other factors include those associated with
clinical studies and manufacturing, as well as development and
commercialization of the Company’s products; the need for
additional financing to maintain operations; risks posed by the
economic and political environments in which the Company operates
and intends to operate; market instability due to the COVID-19
pandemic; the potential for losses arising from the expansion of
operations into new markets; increased competition; assumptions
regarding market trends and the expected demand and desires for the
Company’s products and proposed products; reliance on industry
manufacturers, suppliers and key personnel; the failure to
adequately protect intellectual property; a failure to adequately
manage future growth; adverse market conditions; and failure to
satisfy ongoing regulatory requirements or obtain regulatory
approvals. These forward‐looking statements speak only as of the
date of this news release and, other than as required by applicable
securities laws, the Company undertakes no obligation to revise or
update any forward‐looking statements, even if new information
becomes available in the future.
This news release may also contain estimates and other
statistical, market and industry data from independent parties or
made by the Company relating to our industry. This data involves a
number of assumptions and limitations, and you are cautioned not to
give undue weight to such estimates. We cannot guarantee the
accuracy and completeness of information from third party
sources.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211008005029/en/
Bristol Investor Relations Stefan Eftychiou 905 326 1888 ext 6
stefan@bristolir.com https://www.alphacognition.com/
Alpha Cognition (TSXV:ACOG)
過去 株価チャート
から 12 2024 まで 1 2025
Alpha Cognition (TSXV:ACOG)
過去 株価チャート
から 1 2024 まで 1 2025
